Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27643139 | 0.88 | CDA (0.40) | CDAMAPTPYGMLMNAMTOR | |
| SCHEMBL31685351 | 0.87 | MEN1 (0.35) | CDAMAPTTK2 | |
| SCHEMBL31685169 | 0.84 | ADORA1 (0.39) | — | |
| SCHEMBL31685179 | 0.83 | UMPS (0.45) | — | |
| SCHEMBL114650 | 0.79 | LMNA (0.45) | CDAMAPTPYGMLMNAMTOR | |
| SCHEMBL31685741 | 0.76 | LGALS8 (0.35) | CDAMAPTTK2 | |
| Phosphoric Acid SCHEMBL20305093 | 0.75 | LMNA (0.42) | CDAMAPTPYGMLMNAMTOR | |
| Phosphoric Acid SCHEMBL6465085 | 0.75 | LMNA (0.42) | CDAMAPTPYGMLMNAMTOR | |
| SCHEMBL31685237 | 0.75 | CDA (0.43) | CDAMAPTPYGMTK2 | |
| SCHEMBL31685355 | 0.74 | CDA (0.42) | CDAMAPTPYGMLMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388886-A1 | Cas12a Endonuclease Variants and Methods of Use | ENSOMA APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-4460566-A2 | CAS12A ENDONUCLEASE VARIANTS AND METHODS OF USE | Ensoma ApS (DK) | 2024-11-13 | — | — | EP | disclosed |
| CN-118742641-A | CAS12A endonuclease variants and methods of use | 安索玛私人有限责任公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023131870-A2 | ENDONUCLEASE VARIANTS AND METHODS OF USE | TWELVE BIO APS (DK) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388886-A1 | Cas12a Endonuclease Variants and Methods of Use | CDA, MUS81, DNASE1L3 | CDA 1/4885MAPT 2832/4885PYGM 872/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | CDA 275/4885MAPT 953/4885PYGM 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.